Immunodiagnostic tools have exhibited preeminent potential in disease screening, diagnosis, monitoring, and prognosis. Creative Biolabs has launched our unique antibody & immunoassay development services targeting different disease biomarkers. We are committed to providing the best quality services for the development of in vitro diagnostic (IVD) antibodies and immunoassays.
Fig.1 A map of breast cancer development and progression.1 Breast cancer is cancer that develops from breast tissue. Currently, breast cancer is the most common invasive cancer in women as well as the second main cause of cancer death. Usually, the symptoms of breast cancer include a lump in the breast, dimpling of the skin, fluid coming from the nipple, or a red scaly patch of skin. The exact cause remains unclear, but some risk factors make it more likely, such as a history of breast cancer or breast lumps, alcohol consumption, older age, estrogen exposure, and breastfeeding. Moreover, inherited factors are involved such as women who carry the BRCA1 and BRCA2 genes have a higher risk of developing breast cancer. The management of breast cancer varies under different conditions, depending on the stage of cancer and the age of the patient. In general, it is usually treated with surgery, followed by chemotherapy or radiation therapy, or both. Other treatments include hormone-blocking therapy, monoclonal antibodies, and other immune-modulating treatments.
Initial breast cancer screening is often performed with mammography, which produces images that can help detect any lumps or abnormalities. Once a patient has a suspicious abnormality on screening mammography, further diagnosis can be conducted such as an ultrasound scan that can help differentiate between a solid mass or a fluid-filled cyst, and a magnetic resonance imaging (MRI) scan that helps to find out how far cancer has spread. Confirmed abnormalities on diagnostic mammography or magnetic resonance imaging should be evaluated with an image-guided core needle biopsy. Core biopsy is performed to obtain samples for analysis of histologic and immunohistochemical features of breast cancer.
Breast cancer is divided into in situ (ductal and lobular) and invasive disease. They are characterized by many morphological, clinical, and molecular features, and thus correct classification provides important prognostic information and can affect treatment response. Traditionally, breast cancer has been classified according to histopathologic criteria, including grade, tumor size, and lymph node involvement, also known as the tumor, node, and metastasis (TNM) staging system. Also, clinical criteria including immunohistochemical markers [i.e. estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)], are routinely used in diagnostic laboratories to provide a classification of breast cancer and to help determine the optimal approach for treatment. Moreover, there are several new biomarkers that have been proposed for routine use in the management of breast cancer patients including ER-β, androgen receptor (AR) and Ki-67. With the development of genomic and transcriptomic technologies, more and more new biomarkers will be identified for breast cancer development and management.
Creative Biolabs offers first-class development services of antibodies & immunoassays against different biomarkers to clients globally aiming to improve the diagnosis and classification of cancer subtypes. Our services are customized to meet the purpose of satisfying every specific requirement. The services are mile-stoned and for more detailed information, please click the following links:
Our services can be tailored targeting different biomarkers with potential for breast cancer diagnosis and prognosis, including but not limited to:
| GELS | CA15-3 | PgR | HER2 | ER | uPA |
| PAI-1 | CK19 | CA27.29 | Cathepsin D | Cyclin E | Nestin |
| MUC1/Y | 8-OHdG | TPA | CXCR4 | Mammaglobin | B7-H4 |
| Prostasin | Midkine | StarD10 | FTL |
Please feel free to contact us for more information and discuss your project needs.
Reference
For Research Use Only.
